News Results for Motif Bio Ord 1p (MTFB)
-
12 Oct
09:08Motif Bio posts loss; in reverse takeover discussionsCash shell Motif Bio posted a first-half loss and said it had closely reviewed more than 30 reverse takeover opportunities. Net losses for the six months through June amounted to $0.99 million,...
-
01 Jun
09:38Motif Bio in talks with reserve takeover candidates in healthcare sectorCash shell Motif Bio said it was in negotiations with several reverse takeover candidates in the healthcare sector. The company also announced that it had hired Peel Hunt as an adviser to help it...
-
05 May
09:04Cash shell Motif Bio raises capital for balance sheet, working capitalCash shell Motif Bio said it had raised £0.65m via a share placing to an institutional investor. New shares in the company were issued at 0.4p each. Proceeds would be used to strengthen the...
-
04 May
07:28Motif Bio CEO Graham Lumsden stands down; becomes directorMotif Bio, which was recently reclassified as a cash shell, said chief executive Graham Lumsden had stood down and become a non-executive director. Chief financial officer Jonathan Gold had...
-
27 Nov
07:59Motif Bio gives notice to terminate American depositary shares programMotif Bio said it had given notice to Bank of New York Mellon to terminate its American depositary shares program and warrant agent agreement. The move came after the company on Monday announced...
-
18 Nov
13:19Motif Bio directors stand down in bid to cut costsAntibiotics developer Motif Bio said five of its non-executive directors had stood own as part of move to minimise costs and preserve capital. Craig Albanese, Charlotta Ginman, Zaki Hosny, Mary...
-
11 Nov
07:39Motif Bio subsidiary settles with formal clinical researcherMotif Bio said a subsidiary had reached agreement with its former clinical research organisation to settle all obligations without further payment. The pact would result in the reversal of a...
-
02 Oct
07:26Motif Bio raises capital for planned restructureAntibiotics developer Motif Bio said it had raised $0.6m from a share issue to provide additional working capital for a planned restructuring. New shares in the company were issued at 0.42p each....
-
02 Sep
07:22Motif Bio secures debt repayment extension from Hercules CapitalAntibiotics developer Motif Bio said lender Hercules Capital had agreed to push back the company's next amortisation date to 1 October, from 1 September. The change would mean that the September...
-
19 Aug
07:42Motif Bio to evaluate potential new treatment for Listeria infectionsAntibiotics developer Motif Bio said it would commence a study to evaluate the effectiveness of a treatment candidate against Listeria. Motif Bio said it would utilise NIAID's suite of preclinical...
-
19 Jul
07:47Motif Bio market value falls below Nasdaq listing standardsClinical-stage biopharmaceutical Motif Bio said its market value had slipped below a minimum threshold required for it to be listed on the Nasdaq. The company said it had received a deficiency...
-
15 Jul
08:30Motif Bio submits meeting request with FDA for lead product candidateAntibiotics developer Motif Bio said it had submitted a meeting request and package to the US Food & Drug Administration. The request was related to the company's lead product candidate,...
-
24 Jun
09:45Motif Bio presents data on antibiotic studies at San Francisco conferenceMotif Bio said new data regarding its antibiotic development work had been presented at a key conference in San Francisco. The iclaprim data were presented at the American Society For...
-
22 May
09:39Motif Bio forms research agreement with Otto-von-Guericke University MagdeburgMotif Bio said it had signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in-vitro model of ocular toxoplasmosis. The research would focus...
-
01 May
08:31Motif Bio forms treatment cooperation pact with Lamellar BiomedicalMotif Bio said it had signed an agreement with Lamellar Biomedical under which the companies would investigate a combination of their offerings. The arrangement would see Motif Bio conduct an in...
-
15 Apr
09:30Motif Bio losses narrow as R&D expenses fallAntibiotics developer Motif Bio booked an narrower annual loss as it cut R&D spending. Pre-tax losses for the year through December amounted to $14.0m, narrowing from losses of $44.8m...
-
26 Mar
08:34Motif Bio raises £2.7m from share issueAntibiotics developer Motif Bio said it had raised £2.7m from a share placing to provide additional working capital. New shares in the company were issued at 6p each. The company recently...
-
20 Mar
07:33Motif Bio to meet with FDA to discuss skin infection treatment approvalAntibiotics developer Motif Bio said the US Food & Drug Administration had granted its request for a meeting to discuss iclaprim for the treatment of acute bacterial skin and skin structure...
-
18 Mar
07:16Motif Bio chairman Richard Morgan stands downAntibiotics developer Motif Bio said Richard C. E. Morgan had resigned with immediate effect to focus on other business commitments. Current director Bruce Williams has been appointed interim...
-
18 Feb
08:32Motif Bio to raise capital after making early debt repaymentAntibiotic developer Motif Bio said it would need to raise capital after it made an early debt repayment to Hercules Capital. The company said it would make an immediate early repayment of $7m and...
-
03 Oct
13:39Motif Bio presents wound treatment data at San Francisco conferenceBio-pharmaceutical company Motif Bio said it would present data on its wound treatment at an industry conference in San Francisco. The data for its iclaprim treatment would be presented at IDWeek...
-
28 Sep
09:59Motif Bio shareholder Amphion extends loan repayment by a yearAntibiotics developer Motif Bio noted that substantial shareholder Amphion Innovations had agreed to repayment of a loan by one year until 30 September 2019. Amphion's loan facility was secured by...
-
25 Sep
09:30Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1pPeel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 95p (from 102p). Story provided by StockMarketWire.com Broker Forecasts data...
-
25 Sep
07:30Motif Bio losses narrow on lower R&D spendAntibiotics developer Motif Bio booked a narrowing of first half losses after it cut back on R&D spending. Net losses for the six months through June narrowed to $7.8m, from $29.7m on-year....
-
05 Sep
07:41Motif Bio presents skin treatment study data at Lisbon conferenceAntibiotic developer Motif Bio said it was presenting data on the skin treatment iclaprim at an industry conference in Lisbon. The safety study data was being presented at the European Society of...
-
21 Aug
09:04Amphion Innovations cuts holding in Motif Bio to 8.5%Antibiotics developer Motif Bio noted that Amphion Innovations had sold some of its holding in the company to an institutional investor. Amphion now held 8.51% of the issued share capital of Motif...
-
17 Aug
07:19Motif Bio to present antibiotic treatment data at Lisbon conferenceMotif Bio said data about its iclaprim antibiotic treatment would be presented at an upcoming industry conference in Lisbon. The European Society of Clinical Microbiology and Infectious Diseases...
-
14 Aug
07:45Motif Bio skin infection treatment accepted for filing by FDAMotif Bio said the US Food & Drug Administration had accepted for filing its new drug application for an antibiotic that treats acute bacterial skin and skin structure infections. The...
-
16 Jul
11:50Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1pNorthland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 116p. Story provided by StockMarketWire.com Broker Forecasts data...
-
03 Jul
09:25Motif Bio says director Robert Bertoldi to resignAntibiotics developer Motif Bio said that Robert Bertoldi would resign from its board, effective 16 July. 'On behalf of the board, we are grateful to Bob for his dedication and service to the...
-
14 Jun
07:41Motif Bio completes rolling submission of NDA to the FDA for iclaprimMotif Bio announced the completion of its rolling submission of a new drug application (NDA) to the US Food & Drug Administration (FDA) for iclaprim. Iclaprim is a targeted, Gram-positive...
-
11 Jun
09:15Motif Bio presents skin infection treatment test results at Atlanta conferenceMotif Bio said it had presented findings from a trail of a treatment for bacterial skin infections at a conference in Atlanta. Data from two Phase 3 trials of the investigational drug candidate...
-
08 May
11:10Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1pNorthland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 115p. Story provided by StockMarketWire.com Broker Forecasts data...
-
13 Apr
08:00Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1pPeel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 102p (from 106p). Story provided by StockMarketWire.com Broker Forecasts data...
-
10 Apr
10:02Motif Bio losses deepen on higher staff remunerations costsAntibiotics developer Motif Bio said annual losses deepened, partly due to a rise in staff remuneration costs as it grew its headcount. Pre-tax losses amounted to $44.8m, compared to red ink of...
-
04 Apr
11:50Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1pPeel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 106p. Story provided by StockMarketWire.com Broker Forecasts data provided by...
-
03 Apr
08:07Motif Bio starts rolling submission to FDA skin infection treatmentAntibiotic developer Motif Bio said it had initiated a rolling submission for a new drug application to the US Food & Drug Administration for a treatment for skin infections. The submission,...
-
20 Mar
13:00Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1pPeel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 106p (from 107p). Story provided by StockMarketWire.com Broker Forecasts data...
-
20 Mar
09:53Motif Bio delays new drug application to FDA for skin-infection treatmentMotif Bio said it had delayed a new drug application to the US Food and Drug Administration for a skin-infection treatment in order improve the quality of its submission. 'In consultation with its...
-
02 Feb
15:07Motif Bio CFO resignsMotif Bio said chief financial officer Robert Dickey had resigned. A search process for a new CFO had commenced, the company said. Jonathan E. Gold, currently a non-executive director, had...
-
19 Jan
08:02Motif Bio files US funding registration requestMotif Bio has filed a shelf registration statement with the US Securities and Exchange Commission, which it said would provide it with more timely and efficient access to the US capital markets....
-
05 Jan
09:17Motif Bio CEO to present at summitMotif Bio said chief executive Graham Lumsden would participate in a panel discussion today at the Cantor Antibiotics Summit in New York. The topic of discussion is "Catalysts to Look for in...
-
15 Nov
09:18Motif Bio secures $20m debt financingMotif Bio has secured up to $20m in debt financing with Hercules Capital to fund preparation activities ahead of the US launch of iclaprim in 2019. The first tranche of $15m will be drawn down...
-
06 Oct
08:16Motif Bio presents drug trial dataMotif Bio has presented new pre-clinical data regarding its investigational drug candidate iclaprim to the IDWeek 2017 conference in San Diego. "The data presented today underscore the potential...
-
05 Oct
09:00Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1pPeel Hunt today initiates coverage of Motif Bio Plc Ord 1p (LON:MTFB) with a buy investment rating and price target of 106p. Story provided by StockMarketWire.com
-
04 Oct
16:45Potential energy cap hits Centrica and SSEUK Prime Minister Theresa May's proposed energy cap dragged on UK-listed energy giants British Gas owner Centrica (CNA) and SSE (SSE). Shares in Centrica slumped 6.1% to 179.3p and SSE declined...
-
04 Oct
11:41Utility stocks and Shell weigh on FTSEThe FTSE 100 was weighed down by weakness in utility stocks and Royal Dutch Shell (RDSB), causing the index to dip to 7,464. Rumours that UK Prime Minister Theresa May would bring in an energy cap...
-
29 Sep
07:54Motif Bio losses increaseMotif Bio reported a net loss for the six months ended 30 June 2017 and 2016 was $29.7m and $14.2m, respectively. BUSINESS UPDATE: - On April 18 2017, we announced positive top-line results from...
-
31 Aug
13:30Motif Bio to present at Rodman & Renshaw conferenceMotif Bio has confirmed that the Company will be presenting at the Rodman & Renshaw 19th Annual Global Investment Conference, to be held between the 10th and 12th of September. In addition,...
-
07 Jun
10:50Broker Forecast - finnCap issues a broker note on Motif Bio Plc Ord 1pfinnCap today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 100p (from 125p). Story provided by StockMarketWire.com
-
02 Jun
08:53FTSE jogs higher on mixed bag and resources prices fallThe FTSE 100 is jogging higher in early deals thanks to gains across a palette of sectors, although the resources sector was under pressure. The early rise came after the US last night flagged it...
-
02 Jun
07:12Motif Bio proposes raising £19.4m in placingMotif Bio intends to raise about £19.4m via a conditional placing with new and existing investors to fund the further development of iclaprim, its novel antibiotic candidate. The placing was being...
-
02 Jun
07:05FLASH: Motif Bio proposes raising £19.4m in placingStory provided by StockMarketWire.com
-
18 Apr
09:10Miners slump on sharp drop in metals pricesAs investors returned to the UK markets following the long Easter weekend, there was little corporate news to stir the FTSE 100. Commodity prices slumped across the board with iron and copper the...
-
18 Apr
07:25Motif Bio announces positive topline resultsMotif Bio announced positive topline results from REVIVE-1, a global Phase 3 clinical trial of its investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure...
-
04 Apr
08:10Broker Forecast - finnCap issues a broker note on Motif Bio Plc Ord 1pfinnCap today initiates coverage of Motif Bio Plc Ord 1p (LON:MTFB) with a buy investment rating and price target of 125p. Story provided by StockMarketWire.com
-
01 Feb
09:20Broker Forecast - Beaufort Securities issues a broker note on Motif Bio Plc Ord 1pBeaufort Securities today reaffirms its speculative buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 110p. Story provided by StockMarketWire.com
-
31 Jan
07:42MTFB's Phase 3 clinical trial finishes patient treatmentMotif Bio says the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and...
-
31 Jan
07:08FLASH: Motif Bio's Phase 3 clinical trial finishes patient treatmentStory provided by StockMarketWire.com
-
18 Jan
07:45Motif Bio appoints chief financial officerMotif Bio said that Robert Dickey IV has been appointed as Chief Financial Officer. It said Pete Meyers is leaving the company and has agreed to transition the CFO responsibilities to Dickey over...
-
18 Jan
07:06FLASH: Motif Bio appoints chief financial officerStory provided by StockMarketWire.com
-
14 Dec
12:50Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1pNorthland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 90p (from 140p). Story provided by StockMarketWire.com
-
31 Oct
07:05FLASH: Motif Bio updates on US Public OfferingStory provided by StockMarketWire.com
-
08 Sep
07:42Motif Bio updates on Revive-1 Phase 3 clinical trialMotif Bio has provided an update on REVIVE-1, one of its two Phase 3 clinical trials currently enrolling patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Patient...
-
08 Sep
07:10FLASH: Motif Bio updates on Revive-1 Phase 3 clinical trialStory provided by StockMarketWire.com
-
17 Aug
11:10Broker Forecast - Beaufort Securities issues a broker note on Motif Bio Plc Ord 1pBeaufort Securities today downgrades its investment rating on Motif Bio Plc Ord 1p (LON:MTFB) to hold (from speculative buy). Story provided by StockMarketWire.com
-
16 Aug
07:44Motif Bio widens H1 pretax lossMotif Bio widens H1 pretax loss of $14.2m, from a loss of $1.9m. It is pleased that lead product iclaprim is in its final stage of development. This followed the the dosing of the first patient...
-
16 Aug
07:03FLASH: Motif Bio widens H1 pretax lossStory provided by StockMarketWire.com
-
09 Aug
07:46Motif Bio defers US proposed US public offeringMotif Bio said that due to market conditions it has deferred pricing of its proposed public offering of American Depositary Shares and listing of these on the NASDAQ Global Market. "However, the...
-
09 Aug
07:07FLASH: Motif Bio updates on timing of proposed US IPOStory provided by StockMarketWire.com
-
13 Jul
09:44Amphion partner Motif Bio to list on NASDAQAmphion Innovations' partner company Motif Bio has filed a registration with the US Securities and Exchange Commission for a proposed public offering American Depositary Shares. Motif Bio has also...
-
13 Jul
07:47Motif Bio files for proposed US public offeringMotif Bio has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC) relating to a proposed public offering of American Depositary Shares (ADSs). Motif...
-
13 Jul
07:09FLASH: Motif Bio files For proposed US public offeringStory provided by StockMarketWire.com
-
02 Jun
15:40Motif Bio resolutions passed at AGMMotif Bio has confirmed that all resolutions proposed at its annual general meeting today were passed. At 3:40pm: (LON:MTFB) Motif Bio Plc Ord 1p share price was -1p at 51p Story provided by...
-
20 Apr
09:40Motif Bio materially widens FY pretax lossMotif Bio has materially widened its FY pretax loss to USD8.5m, from a year-earlier loss of USD1.2m. General and administrative expenses rose to USD3.6m, from USD1.1m, while R&D expenses hit...
-
20 Apr
07:08FLASH: Motif Bio materially widens FY pretax lossStory provided by StockMarketWire.com
-
14 Apr
07:03FLASH: Motif Bio updates on senior appointmentsStory provided by StockMarketWire.com
-
02 Mar
07:48MTFB says first patient dosed in iclaprim in Phase 3Motif Bio confirms the dosing of the first patient in two Phase 3 clinical trials of its lead antibiotic candidate iclaprim, for the treatment of acute bacterial skin and skin structure infections...
-
02 Mar
07:17FLASH: MTFB says first patient dosed in iclaprim in Phase 3Story provided by StockMarketWire.com
-
25 Jan
07:09FLASH: Motif Bio appoints US finance adviser and auditorStory provided by StockMarketWire.com
-
15 Dec
07:41MTFB says Iclaprim clinical trial supplies madeMotif Bio said clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial...
-
15 Dec
07:09FLASH: MTFB says Iclaprim clinical trial supplies madeStory provided by StockMarketWire.com
-
07 Dec
13:52Motif Bio to present at Biotech ShowcaseMotif Bio, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has been selected to present at the Biotech Showcase 2016, San Francisco, on 11 January at...
-
24 Nov
09:30Motif Bio updates on IclaprimMotif Bio has received written concurrence from the US Food & Drug Administration (FDA) for an optimized fixed dose of iclaprim of 80mg for all patients except those with moderate hepatic...
-
24 Nov
07:17FLASH: Motif Bio updates on IclaprimStory provided by StockMarketWire.com
-
19 Oct
11:11Motif Bio to make presentation at investor evening in LondonMotif Bio (MTFB) (MTFB.L) [LON.MTFB], a clinical stage biopharmaceutical company specialising in developing novel antibiotics, will be giving a briefing to investors in London early next month. It...
-
16 Oct
07:39MTBF says leading CRO to hold Iclaprim Phase III TrialsMotif Bio confirms the signing of a Phase III clinical trials agreement with Covance, a Contract Research Organisation (CRO) and subsidiary of Laboratory Corp. The trials are for iclaprim, a...
-
16 Oct
07:10FLASH: MTBF says leading CRO to hold Iclaprim Phase III TrialsStory provided by StockMarketWire.com
-
05 Oct
17:05Director Deals - Motif Bio Plc Ord 1p (MTFB)John Stakes, Non Executive Director, bought 100,000 shares in the company on the 2nd October 2015 at a price of 60.00p. The Director now holds 171,850 shares. Story provided by...
-
23 Sep
15:08Motif issues sharesMotif Bio has announced that it has issued 140,321 new Ordinary Shares in settlement of an exercise of warrants. The exercise price of the warrants was 20 pence. The new Ordinary Shares represent...
-
03 Sep
07:19MTFB's designationMotif Bio said the US Food and Drug Administration (FDA) has granted Fast Track designation for iclaprim intravenous (IV) to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and...
-
03 Sep
07:04FLASH: Motif Bio says FDA fast tracks IclaprimStory provided by StockMarketWire.com
-
02 Sep
13:28Motif Bio appoints investor relations adviser in USMotif Bio has appointed Westwicke Partners as investor relations adviser in the US. Motif chief executive Graham Lumsden said: "We look forward to building a relationship with the Westwicke team...
-
27 Aug
09:22Motif Bio continues development of new antibioticMotif Bio (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has announced its maiden interim financial results as an AIM-listed company. The...
-
22 Jul
07:16FLASH: Motif Bio says final condition of £22m placing satisfiedStory provided by StockMarketWire.com
-
20 Jul
13:40Motif Bio options exercisedMotif Bio has issued 25,147 ordinary shares following the exercise of options by a former employee. The options were exercised at prices of $0.20877 and $0.69589 per ordinary share for total...
-
17 Jul
07:19Motif Bio says FDA approves iclaprim as QIDPMotif Bio said the US Food & Drug Administration (FDA) has designated iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP) Iclaprim is a...
-
17 Jul
07:12FLASH: Motif Bio says FDA approves iclaprim as QIDPStory provided by StockMarketWire.com
-
10 Jul
13:40Motif Bio resolutions passedMotif Bio has announced that at the General Meeting held earlier today all resolutions were duly passed. At 1:40pm: (LON:MTFB) Motif Bio Plc Ord 1p share price was 0p at 64p Story provided...
-
23 Jun
08:53Amphion partner company raises £22mAmphion Innovations partner company Motif Bio has raised £22m, gross, through a conditional placing of 44,000,000 new ordinary shares at 50p apiece with institutional investors. The placing is...